Division of Neonatology, Department of Pediatrics, Ankara University Faculty of Medicine, 06590, Mamak, Ankara, Turkey.
Division of Pediatric Intensive Care, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey.
Eur J Pediatr. 2023 Nov;182(11):4897-4908. doi: 10.1007/s00431-023-05162-2. Epub 2023 Aug 19.
Continuous kidney replacement therapy (CKRT) use has increased in recent years, but anticoagulation is a challenge for neonates. Regional citrate anticoagulation (RCA) is rarely preferred in neonates because of citrate accumulation (CA) and metabolic complications. We aimed to demonstrate the efficacy and safety of RCA in neonates. We retrospectively analyzed the medical records of 11 neonates treated with RCA-CKRT between 2018 and 2023. The initial dose of RCA was 2.1-3 mmol/l, and then, its dose was increased according to the level of ionized calcium (iCa) in the circuit and patients. The total/iCa ratio after-treatment > 2.5 was indicated as CA. We evaluated to citrate dose, CA, circuit lifespan, and dialysis effectivity. The median gestational age was 39 (36.4-41.5) weeks, the median body weight (BW) was 3200 (2400-4000) grams, and the mean postnatal age was 4 (2-24) days. The most common indication for CKRT was hyperammonemia (73%). All neonates had metabolic acidosis and hypocalcemia during CKRT. Other common metabolic complications were hypophosphatemia (90%), hypokalemia (81%), and hypomagnesemia (63%). High dialysate rates with a median of 5765 ml/h/1.73 m allowed for a rapid decrease in ammonia levels to normal. Four patients (36.3%) had CA, and seven (63.7%) did not (non-citrate accumulation, NCA). Mean BW, median postnatal age, biochemical parameters, coagulation tests, and ammonia levels were similar between the CA and NCA groups. Low pH, low HCO, high lactate, and SNAPPE-II scores could be associated with a higher T/iCa ratio.
RCA was an efficient and safe anticoagulation for neonates requiring CKRT. Metabolic complications may occur, but they could be managed with adequate supplementation.
• Continuous kidney replacement therapy (CKRT) has become popular in recent years due to its successful treatment of fluid overload, electrolyte imbalance, metabolic acidosis, multi-organ failure, and hyperleucinemia/hyperammonemia associated with inborn errors of metabolism. • The need for anticoagulation is the major difficulty in neonatal CKRT. In adult and pediatric patients, regional citrate anticoagulation has been shown to be effective.
• RCA is an effective and safe anticoagulation method for neonates who require CKRT. • Electrolyte imbalances and metabolic acidosis could be managed with adequate supplementation and appropriate treatment parameters such as citrate dose, blood flow rate, and dialysate flow rate.
连续肾脏替代治疗(CKRT)近年来应用增多,但新生儿抗凝是一大挑战。由于柠檬酸蓄积(CA)和代谢并发症,区域枸橼酸抗凝(RCA)在新生儿中很少被首选。我们旨在证明 RCA 在新生儿中的疗效和安全性。我们回顾性分析了 2018 年至 2023 年期间接受 RCA-CKRT 治疗的 11 例新生儿的病历。RCA 的初始剂量为 2.1-3mmol/L,然后根据回路和患者的离子钙(iCa)水平增加其剂量。治疗后总钙/iCa 比值>2.5 表示 CA。我们评估了枸橼酸盐剂量、CA、回路寿命和透析效果。中位胎龄为 39(36.4-41.5)周,中位体重(BW)为 3200(2400-4000)克,平均生后年龄为 4(2-24)天。CKRT 的最常见适应证是高血氨(73%)。所有新生儿在 CKRT 期间均存在代谢性酸中毒和低钙血症。其他常见的代谢并发症包括低磷血症(90%)、低钾血症(81%)和低镁血症(63%)。高透析液率中位数为 5765ml/h/1.73m2 ,可迅速将血氨水平降至正常。4 例患者(36.3%)出现 CA,7 例患者(63.7%)未出现 CA(非枸橼酸盐蓄积,NCA)。CA 组和 NCA 组的平均 BW、中位生后年龄、生化参数、凝血试验和血氨水平相似。低 pH 值、低 HCO3-、高乳酸和 SNAPPE-II 评分可能与较高的 T/iCa 比值相关。
RCA 是新生儿 CKRT 的一种有效且安全的抗凝方法。可能发生代谢并发症,但通过适当补充可以进行管理。
• 连续肾脏替代治疗(CKRT)近年来因其成功治疗液体超负荷、电解质失衡、代谢性酸中毒、多器官衰竭以及与先天性代谢错误相关的高白细胞血症/高血氨而受到广泛关注。• 新生儿 CKRT 的主要难点在于抗凝。在成人和儿科患者中,已证明区域枸橼酸抗凝是有效的。
• RCA 是需要 CKRT 的新生儿的一种有效且安全的抗凝方法。• 通过适当补充和适当的治疗参数(如枸橼酸盐剂量、血流速度和透析液流速),可以管理电解质失衡和代谢性酸中毒。